David Ege

Black and white headshot of Eric Shaff

Eric Shaff

PRESIDENT, CHIEF EXECUTIVE OFFICER

Black and white headshot of John Aunins

John Auniņš Ph.D.

SENIOR ADVISOR

Black and white headshot of Kelly Brady

Kelly M. Brady

VP, CLINICAL OPERATIONS

Black and white headshot of Marcus Chapman

Marcus Chapman

SVP, PRINCIPAL FINANCIAL OFFICER

Black and white headshot of Gloria Cosgrove

Gloria G. Cosgrove

VP, QUALITY SYSTEMS

Black and white headshot of Thomas Desrosier

Thomas J. DesRosier, Esq.

EVP, CHIEF LEGAL OFFICER AND SECRETARY

Close bio

David Ege is the Executive Vice President and Chief Technology Officer of Seres. He has more than 15 years of experience in the pharmaceutical industry, with a focus on vaccine and biologics manufacturing, facility development and process optimization. Prior to joining Seres, Dr. Ege had been at Merck since 2003, in a variety of technical and leadership roles in R&D and manufacturing, in the U.S. and Switzerland. His most recent role was global lead for digital strategy in Merck’s Manufacturing Division. From 2015-2019, Dr. Ege served as Executive Director of Vaccines & Biologics Manufacturing at Merck’s plant in Elkton, VA where he led bulk manufacturing operations for the Gardasil® and Gardasil9® cervical cancer vaccines, as well as adjuvants and Cancidas® – a broad-based anti-fungal medicine made by fermentation. He has contributed to the successful first-in-class licensure and launch of cervical cancer vaccines, Gardasil® (2006) and Gardasil9® (2014), and a breakthrough cancer immunotherapy, Keytruda® (2014). He graduated summa cum laude from Princeton with a BSE in chemical engineering in 1996, and earned his Ph.D. in chemical engineering from the University of Pennsylvania in 2003. While at Penn, Dave also worked in the University’s Center for Technology Transfer and served as President of the Penn Biotech Group.